![conference banner](/images/conference-banner.jpeg)
摘要
背景:主要目标是分析患者变量(抑郁,生活质量,抗痴呆药物治疗,痴呆相关知识)与正式诊断为痴呆的社区住院初级保健患者的筛查阳性痴呆。 方法:DelpHi-MV(痴呆:梅克伦堡 - 前波美拉尼亚的生活和以人为中心的帮助)是一项基于全科医生的随机对照干预试验。目前的分析是基于319名筛查阳性的筛查患者(70岁以上,居住在家中)在筛查之前未被正式诊断为痴呆的横断面数据。医疗诊断(ICD-10)是从患者的病历中检索出来的。在基线检查的筛查测试后,评估抑郁症(老年抑郁量表; GDS),阿尔茨海默病(QOL-AD)的生活质量,痴呆知识和抗痴呆药物治疗。 结果:在基线检查中,319例患者中有171例(54%)在筛查阳性后被正式诊断为痴呆。 (GDS≥6:11%vs. 15%; p = 0.396),生活质量(平均(SD):2.8(0.3)vs. 2.8(0.4)),单因素比较显示, ; p = 0.833)和痴呆相关知识(75%vs 75%; p> 0.999)。接受正规诊断的患者更常使用抗痴呆药物(20%比11%; p = 0.040)。控制混杂变量的多变量分析证实了这些发现。 结论:目前的研究结果并不支持在筛查后确定正式的痴呆诊断与潜在的危害有关的担忧。如果在前瞻性研究中得到证实,我们的数据表明患者可能从正式诊断为抗痴呆药物治疗中受益。
关键词: 痴呆症,筛查,初级保健,痴呆症的正式诊断,抑郁症,生活质量,抗痴呆药物治疗,DelpHi试验。
Current Alzheimer Research
Title:Patient Variables Associated with the Assignment of a Formal Dementia Diagnosis to Positively Screened Primary Care Patients
Volume: 15 Issue: 1
关键词: 痴呆症,筛查,初级保健,痴呆症的正式诊断,抑郁症,生活质量,抗痴呆药物治疗,DelpHi试验。
摘要: Background: Main objective was to analyze the associations of patient variables (depression, quality of life, anti-dementia drug treatment, knowledge about dementia) with the assignment of a formal diagnosis of dementia to community-dwelling primary care patients who have screened positive for dementia.
Methods: DelpHi-MV (Dementia: life- and person-centered help in Mecklenburg-Western Pomerania) is a general practitioner based randomized controlled intervention trial. Present analyses are based on cross-sectional data of 319 positively screened patients (age 70+, living at home) who had not been formally diagnosed with dementia before the screening. The medical diagnoses (ICD-10) were retrieved from the patient's medical records. Depression (Geriatric Depression Scale; GDS), quality of life in Alzheimer's disease (Qol-AD), knowledge about dementia, and anti-dementia drug treatment were assessed after the screening test at the baseline examination.
Results: At the baseline examination, 171 out of 319 patients (54%) had been formally diagnosed with dementia after they have screened positive. Univariate comparisons showed no statistically significant differences between diagnosed and undiagnosed patients regarding depression (GDS≥6: 11% vs. 15%; p=0.396), quality of life (mean (SD): 2.8 (0.3) vs. 2.8 (0.4); p=0.833), and the knowledge about dementia (75% vs. 75%; p>0.999). Patients who had received a formal diagnosis were more often treated with anti-dementia drugs (20% vs. 11%; p=0.040). Multivariate analyses controlled for confounding variables confirmed these findings.
Conclusion: Present findings do not support concerns that the assignment of a formal dementia diagnosis after screening is associated with potential harms. If confirmed in a prospective study, our data would suggest that patients may benefit from being formally diagnosed regarding anti-dementia drug treatment.
Export Options
About this article
Cite this article as:
Patient Variables Associated with the Assignment of a Formal Dementia Diagnosis to Positively Screened Primary Care Patients, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170908095707
DOI https://dx.doi.org/10.2174/1567205014666170908095707 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets SUMOylation in Neurological Diseases
Current Molecular Medicine Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Neuroinflammation, Diabetes and COVID-19: Perspectives Coming from Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews VDAC-Targeted Drugs Affecting Cytoprotection and Mitochondrial Physiology in Cerebrovascular and Cardiovascular Diseases
Current Medicinal Chemistry Bottom-Up Proteomics
Current Analytical Chemistry Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Moderate Hyperhomocysteinemia and Immune Activation
Current Pharmaceutical Biotechnology AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets Advances in Metal-organic Frameworks (MOFs) based Biosensors for Diagnosis: An Update
Current Topics in Medicinal Chemistry Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Subduing the Green-eyed Monster: Bridging the Psychopharmacological and Psychosocial Treatment Perspective in Understanding Pathological Jealousy
Current Drug Targets Smoking and Cognition
Current Drug Abuse Reviews Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century – A Medicinal Chemistry Survey
Current Topics in Medicinal Chemistry